$AXDX
Accelerate Diagnostics, Inc Stock $axdx

$axdx Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-K Financial Statement

#000162828018002558 Filed on March 01, 2018

Income Statement

Concept	2017 Q4	2017 Q3	2017
Revenue	$2.120M	$828.0K	$4.177M
YoY Change	5335.9%	3350.0%	1597.97%
Cost Of Revenue	$650.0K	$191.0K	$1.002M
YoY Change
Gross Profit	$1.470M	$637.0K	$3.175M
YoY Change	3669.23%	2554.17%	1190.65%
Gross Profit Margin	69.34%	76.93%	76.01%
Selling, General & Admin	$11.47M	$11.60M	$45.06M
YoY Change	12.23%	24.6%	21.18%
% of Gross Profit	780.27%	1821.04%	1419.15%
Research & Development	$6.140M	$6.351M	$22.30M
YoY Change	16.95%	-19.34%	-24.57%
% of Gross Profit	417.69%	997.02%	702.39%
Depreciation & Amortization	$580.0K	$550.0K	$2.200M
YoY Change	-1.69%	-8.03%	-4.35%
% of Gross Profit	39.46%	86.34%	69.29%
Operating Expenses	$17.60M	$6.351M	$67.36M
YoY Change	9.59%	-19.34%	0.92%
Operating Profit	-$16.14M	-$17.32M	-$64.18M
YoY Change	0.7%	-0.58%	-3.48%
Interest Expense	$290.0K	$0.00	$830.0K
YoY Change	81.25%	-100.0%	112.82%
% of Operating Profit
Other Income/Expense, Net	-$180.0K	$285.0K	$649.0K
YoY Change			64.72%
Pretax Income	-$16.02M	-$17.03M	-$63.54M
YoY Change	0.95%	-1.56%	-3.89%
Income Tax	$270.0K	$45.00K	$493.0K
% Of Pretax Income
Net Earnings	-$16.30M	-$17.08M	-$64.03M
YoY Change	1.0%	-1.29%	-3.53%
Net Earnings / Revenue	-768.68%	-2062.2%	-1532.87%
Basic Earnings Per Share
Diluted Earnings Per Share	-$293.8K	-$308.7K	-$1.184M
COMMON SHARES
Basic Shares Outstanding	55.40M shares	55.32M shares	54.07M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q4	2017 Q3	2017
SHORT-TERM ASSETS
Cash & Short-Term Investments	$109.2M	$121.3M	$109.2M
YoY Change	40.36%	34.48%	40.36%
Cash & Equivalents	$28.51M	$34.43M	$28.50M
Short-Term Investments	$80.60M	$86.90M	$80.60M
Other Short-Term Assets	$468.0K	$460.0K	$1.400M
YoY Change	155.74%	350.98%	100.0%
Inventory	$8.063M	$7.341M	$8.100M
Prepaid Expenses	$850.0K
Receivables	$1.900M	$1.100M	$1.900M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$120.5M	$131.3M	$120.5M
YoY Change	53.59%	43.19%	53.7%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.890M	$4.690M	$4.900M
YoY Change	14.84%	-2.33%	13.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00		$0.00
YoY Change
Total Long-Term Assets	$5.024M	$4.827M	$5.000M
YoY Change	14.08%	-2.5%	11.11%
TOTAL ASSETS
Total Short-Term Assets	$120.5M	$131.3M	$120.5M
Total Long-Term Assets	$5.024M	$4.827M	$5.000M
Total Assets	$125.5M	$136.1M	$125.5M
YoY Change	51.49%	40.85%	51.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.080M	$1.369M	$2.100M
YoY Change	109.68%	-42.96%	110.0%
Accrued Expenses	$3.636M	$3.700M	$3.600M
YoY Change	21.2%	85.0%	20.0%
Deferred Revenue	$1.071M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.787M	$6.183M	$6.800M
YoY Change	68.16%	38.98%	70.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$21.00K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Liabilities	$21.00K	$0.00	$0.00
YoY Change		-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.787M	$6.183M	$6.800M
Total Long-Term Liabilities	$21.00K	$0.00	$0.00
Total Liabilities	$6.808M	$6.183M	$6.800M
YoY Change	35.19%	13.47%	36.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$242.0M	-$225.7M
YoY Change	36.48%	40.04%
Common Stock	$360.6M	$355.5M
YoY Change	41.28%	40.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00
YoY Change
Treasury Stock Shares
Shareholders Equity	$118.7M	$129.9M	$118.7M
YoY Change
Total Liabilities & Shareholders Equity	$125.5M	$136.1M	$125.5M
YoY Change	51.49%	40.85%	51.39%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2017
OPERATING ACTIVITIES
Net Income	-$16.30M	-$17.08M	-$64.03M
YoY Change	1.0%	-1.29%	-3.53%
Depreciation, Depletion And Amortization	$580.0K	$550.0K	$2.200M
YoY Change	-1.69%	-8.03%	-4.35%
Cash From Operating Activities	-$13.25M	-$14.41M	-$55.75M
YoY Change	3.52%	15.1%	4.38%
INVESTING ACTIVITIES
Capital Expenditures	-$910.0K	-$420.0K	-$2.970M
YoY Change	727.27%	90.91%	23.24%
Acquisitions
YoY Change
Other Investing Activities	$6.090M	-$14.48M	-$22.76M
YoY Change	121.45%	-546.91%	-51.74%
Cash From Investing Activities	$5.180M	-$14.90M	-$25.73M
YoY Change	95.47%	-593.38%	-48.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.130M	1.030M	$90.43M
YoY Change	173.08%	43.06%	5032.07%
NET CHANGE
Cash From Operating Activities	-13.25M	-14.41M	-$55.75M
Cash From Investing Activities	5.180M	-14.90M	-$25.73M
Cash From Financing Activities	2.130M	1.030M	$90.43M
Net Change In Cash	-5.940M	-28.28M	$8.953M
YoY Change	-36.61%	222.1%	-108.85%
FREE CASH FLOW
Cash From Operating Activities	-$13.25M	-$14.41M	-$55.75M
Capital Expenditures	-$910.0K	-$420.0K	-$2.970M
Free Cash Flow	-$12.34M	-$13.99M	-$52.78M
YoY Change	-2.76%	13.74%	3.49%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015	axdx	Clinical Trial Agreement Expense ClinicalTrialAgreementExpense	1600000	USD
CY2012Q4	axdx	Additional Option Indexed To Issuers Equity Indexed Shares AdditionalOptionIndexedToIssuersEquityIndexedShares	7000000	shares
CY2013Q4	axdx	Additional Option Indexed To Issuers Equity Indexed Shares AdditionalOptionIndexedToIssuersEquityIndexedShares	7000000	shares
CY2016	axdx	Adjustmentsto Additional Paidin Capital Short Swing Profits Netof Costs AdjustmentstoAdditionalPaidinCapitalShortSwingProfitsNetofCosts	866000	USD
CY2013Q4	axdx	Additional Exercised Class Of Warrant Or Right Exercise Price Of Warrants Or Rights AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	2
CY2016Q4	axdx	Additional Exercised Class Of Warrant Or Right Exercise Price Of Warrants Or Rights AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	2
CY2017Q4	axdx	Additional Exercised Class Of Warrant Or Right Exercise Price Of Warrants Or Rights AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	2
CY2012Q4	axdx	Additional Exercised Class Of Warrant Or Right Exercise Price Of Warrants Or Rights2 AdditionalExercisedClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2	2.00
CY2016Q4	axdx	Additional Exercised Option Indexedto Issuers Equity Indexed Shares AdditionalExercisedOptionIndexedtoIssuersEquityIndexedShares	155289	shares
CY2017Q4	axdx	Additional Exercised Option Indexedto Issuers Equity Indexed Shares AdditionalExercisedOptionIndexedtoIssuersEquityIndexedShares	370307	shares
CY2013Q4	axdx	Additional Exercisedl Option Indexed To Issuers Equity Indexed Shares AdditionalExercisedlOptionIndexedToIssuersEquityIndexedShares	6400000	shares
CY2017	axdx	Bundled Rental Agreement Term BundledRentalAgreementTerm	P5Y
CY2013Q4	axdx	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights3 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3	1.03
CY2012Q4	axdx	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights3 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights3	1.03
CY2016	axdx	Clinical Trial Agreement Expense ClinicalTrialAgreementExpense	2100000	USD
CY2017	axdx	Clinical Trial Agreement Expense ClinicalTrialAgreementExpense	27000	USD
CY2012	axdx	Common Stock And Warrants Issued Value CommonStockAndWarrantsIssuedValue	14400000	USD
CY2016Q4	axdx	Deferred Revenue Research Use Only DeferredRevenueResearchUseOnly	35000	USD
CY2017Q4	axdx	Deferred Revenue Research Use Only DeferredRevenueResearchUseOnly	71000	USD
CY2016Q4	axdx	Deferred Tax Assets Finite Lived Intangible Assets DeferredTaxAssetsFiniteLivedIntangibleAssets	220000	USD
CY2017Q4	axdx	Deferred Tax Assets Finite Lived Intangible Assets DeferredTaxAssetsFiniteLivedIntangibleAssets	42000	USD
CY2015	axdx	Effective Income Tax Rate Reconciliation Other Permanent Differences Percent EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent	-0.0011
CY2016	axdx	Effective Income Tax Rate Reconciliation Other Permanent Differences Percent EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent	0.0017
CY2017	axdx	Effective Income Tax Rate Reconciliation Other Permanent Differences Percent EffectiveIncomeTaxRateReconciliationOtherPermanentDifferencesPercent	0.0231
CY2015	axdx	Effective Income Tax Rate Reconciliation Tax Cutsand Jobs Actof2017 Percent EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActof2017Percent	0.0000
CY2016	axdx	Effective Income Tax Rate Reconciliation Tax Cutsand Jobs Actof2017 Percent EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActof2017Percent	0.0000
CY2017	axdx	Effective Income Tax Rate Reconciliation Tax Cutsand Jobs Actof2017 Percent EffectiveIncomeTaxRateReconciliationTaxCutsandJobsActof2017Percent	0.3846
CY2013Q4	axdx	Exercised Warrant Amount Unexercised ExercisedWarrantAmountUnexercised	571160	shares
CY2016Q4	axdx	Exercised Warrant Amount Unexercised ExercisedWarrantAmountUnexercised	415871	shares
CY2017Q2	axdx	Exercised Warrant Amount Unexercised ExercisedWarrantAmountUnexercised	45564	shares
CY2013	axdx	Exercised Warrant Percent Exercised ExercisedWarrantPercentExercised	0.92
CY2013Q4	axdx	Exercisedl Option Indexed To Issuers Equity Indexed Shares ExercisedlOptionIndexedToIssuersEquityIndexedShares	7000000	shares
CY2015	axdx	Proceeds From Recoveryof Related Party Short Swing Profits ProceedsFromRecoveryofRelatedPartyShortSwingProfits	0	USD
CY2016	axdx	Proceeds From Recoveryof Related Party Short Swing Profits ProceedsFromRecoveryofRelatedPartyShortSwingProfits	866000	USD
CY2017	axdx	Proceeds From Recoveryof Related Party Short Swing Profits ProceedsFromRecoveryofRelatedPartyShortSwingProfits	0	USD
CY2015Q4	axdx	Proceeds From Saleof Common Stock Gross ProceedsFromSaleofCommonStockGross	109300000	USD
CY2012Q3	axdx	Revenue Recognition Milestone Method Milestone Jobs Created Milestone Four RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneFour	65	job
CY2012Q3	axdx	Revenue Recognition Milestone Method Milestone Jobs Created Milestone One RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneOne	15	job
CY2012Q3	axdx	Revenue Recognition Milestone Method Milestone Jobs Created Milestone Three RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneThree	40	job
CY2012Q3	axdx	Revenue Recognition Milestone Method Milestone Jobs Created Milestone Two RevenueRecognitionMilestoneMethodMilestoneJobsCreatedMilestoneTwo	30	job
CY2012Q3	axdx	Revenue Recognition Milestone Method Number Of Milestones RevenueRecognitionMilestoneMethodNumberOfMilestones	4	milestone
CY2015	axdx	Share Based Compensation Arrangement By Share Based Payment Award Option Equity Instruments Forfeitures1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1	0.056
CY2016	axdx	Share Based Compensation Arrangement By Share Based Payment Award Option Equity Instruments Forfeitures1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1	0.085
CY2017	axdx	Share Based Compensation Arrangement By Share Based Payment Award Option Equity Instruments Forfeitures1 ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionEquityInstrumentsForfeitures1	0.000
CY2017	axdx	Standard Product Warranty Instruments Term StandardProductWarrantyInstrumentsTerm	P1Y
CY2017	axdx	Standard Product Warranty Kits And Accessories Term StandardProductWarrantyKitsAndAccessoriesTerm	P60D
CY2015Q4	axdx	Underwriting Discountand Commission Fees Per Share UnderwritingDiscountandCommissionFeesPerShare	1.19
CY2015	axdx	Unrecognized Tax Benefits Other Decrease UnrecognizedTaxBenefitsOtherDecrease	0	USD
CY2016	axdx	Unrecognized Tax Benefits Other Decrease UnrecognizedTaxBenefitsOtherDecrease	0	USD
CY2017	axdx	Unrecognized Tax Benefits Other Decrease UnrecognizedTaxBenefitsOtherDecrease	0	USD
CY2015	axdx	Unrecognized Tax Benefits Other Increase UnrecognizedTaxBenefitsOtherIncrease	0	USD
CY2016	axdx	Unrecognized Tax Benefits Other Increase UnrecognizedTaxBenefitsOtherIncrease	0	USD
CY2017	axdx	Unrecognized Tax Benefits Other Increase UnrecognizedTaxBenefitsOtherIncrease	0	USD
CY2017	dei	Amendment Flag AmendmentFlag	false
CY2017	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2017	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017	dei	Document Period End Date DocumentPeriodEndDate	2017-12-31
CY2017	dei	Document Type DocumentType	10-K
CY2017	dei	Entity Central Index Key EntityCentralIndexKey	0000727207
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55766359	shares
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2017Q2	dei	Entity Public Float EntityPublicFloat	841800000	USD
CY2017	dei	Entity Registrant Name EntityRegistrantName	Accelerate Diagnostics, Inc.
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3009000	USD
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3636000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	992000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2080000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4836000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6584000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-204000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	255257000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	360620000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8388000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8775000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14940000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8388000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8775000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13933000	USD
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	10000	USD
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11000	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12000	USD
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6778580	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7313245	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7352281	shares
CY2016Q4	us-gaap	Assets Assets	82852000	USD
CY2017Q4	us-gaap	Assets Assets	125512000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	78448000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	120488000	USD
CY2016Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	69489000	USD
CY2017Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	88480000	USD
CY2016Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	58595000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	80841000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	58519000	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	80648000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	83000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	193000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	58595000	USD
CY2017Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	80841000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	13204000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	25040000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	13175000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	24913000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	45391000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	55801000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	45344000	USD
CY2016Q4	us-gaap	Common Stock Other Value Outstanding CommonStockOtherValueOutstanding	52000	USD
CY2017Q4	us-gaap	Common Stock Other Value Outstanding CommonStockOtherValueOutstanding	56000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-101341000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	9269000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	14000000	shares
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	55735000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	58519000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	80648000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53563000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	120585000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19244000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28513000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	67022000	USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	51516309	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55673810	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	51516309	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55673810	shares
CY2012Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	8500000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45517000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-66566000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-63824000	USD
CY2017Q4	us-gaap	Contractual Obligation ContractualObligation	1454000	USD
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
CY2016	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
CY2017	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1002000	USD
CY2015	us-gaap	Costs And Expenses CostsAndExpenses	45696000	USD
CY2016	us-gaap	Costs And Expenses CostsAndExpenses	66747000	USD
CY2017	us-gaap	Costs And Expenses CostsAndExpenses	67359000	USD
CY2016Q4	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	-655000	USD
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2015	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2016	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	267000	USD
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	493000	USD
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	267000	USD
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	493000	USD
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2012Q3	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	1000000	USD
CY2016Q4	us-gaap	Deferred Credits And Other Liabilities Current DeferredCreditsAndOtherLiabilitiesCurrent	0	USD
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2012Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.03
CY2017Q4	us-gaap	Deferred Credits And Other Liabilities DeferredCreditsAndOtherLiabilities	1000000	USD
CY2017Q4	us-gaap	Deferred Credits And Other Liabilities Current DeferredCreditsAndOtherLiabilitiesCurrent	1000000	USD
CY2016Q4	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	1000000	USD
CY2017Q4	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	0	USD
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2016Q4	us-gaap	Deferred Revenue DeferredRevenue	35000	USD
CY2017Q4	us-gaap	Deferred Revenue DeferredRevenue	1071000	USD
CY2016Q4	us-gaap	Deferred Revenue And Credits DeferredRevenueAndCredits	35000	USD
CY2017Q4	us-gaap	Deferred Revenue And Credits DeferredRevenueAndCredits	1071000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1000000	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2016	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	114000	USD
CY2017	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	0	USD
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	370000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	253000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	1735000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	58000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	42013000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	41086000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	121000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	45000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	690000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	524000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	3984000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	6651000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	7208000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8195000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	56341000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	56854000	USD
CY2015	us-gaap	Depreciation Depreciation	1782000	USD
CY2016	us-gaap	Depreciation Depreciation	2340000	USD
CY2017	us-gaap	Depreciation Depreciation	2184000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1800000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2300000	USD
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0000
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2200000	USD
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.01
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.29
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.18
CY2015	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
CY2016	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-127000	USD
CY2017	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	316000	USD
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0040
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0078
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3581
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2802
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0081
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0067
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.0102
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	-0.0267
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	-0.0331
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	-0.0442
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0042
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0862
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0899
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0000
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0000
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0286
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0117
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0431
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0293
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0169
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0262
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	-0.0040
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	-0.0109
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Contingencies EffectiveIncomeTaxRateReconciliationTaxContingencies	-0.0120
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	15900000	USD
CY2015	us-gaap	Fair Value Inputs Price Earnings Ratio Multiple FairValueInputsPriceEarningsRatioMultiple	16.69
CY2016	us-gaap	Fair Value Inputs Price Earnings Ratio Multiple FairValueInputsPriceEarningsRatioMultiple	10.35
CY2017	us-gaap	Fair Value Inputs Price Earnings Ratio Multiple FairValueInputsPriceEarningsRatioMultiple	16.24
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	146000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	134000	USD
CY2015	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-19000	USD
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-77000	USD
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-75000	USD
CY2015	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18554000	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	37183000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	45058000	USD
CY2015	us-gaap	Gross Profit GrossProfit	147000	USD
CY2016	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-23000	USD
CY2017	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-240000	USD
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-92000	USD
CY2017	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	36000	USD
CY2016Q1	us-gaap	Gross Profit GrossProfit	163000	USD
CY2016Q2	us-gaap	Gross Profit GrossProfit	20000	USD
CY2016Q3	us-gaap	Gross Profit GrossProfit	24000	USD
CY2016Q4	us-gaap	Gross Profit GrossProfit	39000	USD
CY2016	us-gaap	Gross Profit GrossProfit	246000	USD
CY2017Q1	us-gaap	Gross Profit GrossProfit	504000	USD
CY2017Q2	us-gaap	Gross Profit GrossProfit	564000	USD
CY2017Q3	us-gaap	Gross Profit GrossProfit	637000	USD
CY2017Q4	us-gaap	Gross Profit GrossProfit	1470000	USD
CY2017	us-gaap	Gross Profit GrossProfit	3175000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-44415000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-48539000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-46849000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-45498000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-66107000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-63535000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1083000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-17568000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-16686000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-45498000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-66107000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-63535000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.29
CY2016Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.35
CY2016Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.34
CY2016Q4	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.31
CY2017Q1	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.27
CY2017Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.31
CY2017Q3	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.31
CY2017Q4	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.29
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	267000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	493000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	329000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1242000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1064000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-43000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1912000	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	827000	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1619000	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	596000	USD
CY2015	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	0	USD
CY2016	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	0	USD
CY2017	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	21000	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	100000	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	377000	USD
CY2015	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	74000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7759000	USD
CY2015	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	12000	USD
CY2016	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	171000	USD
CY2017	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	285000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1241000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1292000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	174000	USD
CY2015	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-4000	USD
CY2016	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	0	USD
CY2017	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	0	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	0	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3466000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	8063000	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	0	USD
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4220000	USD
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	0	USD
CY2016	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	494000	USD
CY2017	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	908000	USD
CY2015	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-188000	USD
CY2016	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-374000	USD
CY2017	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-326000	USD
CY2016Q4	us-gaap	Investments Investments	58519000	USD
CY2017Q4	us-gaap	Investments Investments	80648000	USD
CY2015	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	104165000	USD
CY2016	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	226000	USD
CY2017	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	83821000	USD
CY2015	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	685000	USD
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1100000	USD
CY2017	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1300000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	5036000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	6808000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	82852000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	125512000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4036000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6787000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	104823000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1762000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	90427000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2675000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-49568000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25728000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35126000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-53408000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55746000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-45498000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-15074000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-17866000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-17299000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-16135000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-66374000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-14200000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-16457000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-17075000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-16296000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-64028000	USD
CY2017	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-45549000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15172000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-17889000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-17416000	USD
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-16024000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-66501000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14310000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-16423000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-17315000	USD
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-16136000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-64184000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1119000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	47000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	84000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	200000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	4000	USD
CY2012Q4	us-gaap	Option Indexed To Issuers Equity Indexed Shares OptionIndexedToIssuersEquityIndexedShares	7000000	shares
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	183000	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	468000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-20000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-64000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-117000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-128000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	321000	USD
CY2015	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	0	USD
CY2016	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	23000	USD
CY2017	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	184000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	21000	USD
CY2015	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	51000	USD
CY2016	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	394000	USD
CY2017	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	649000	USD
CY2015	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	0	USD
CY2016	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	0	USD
CY2017	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	0	USD
CY2015Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5900000	USD
CY2015	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2016	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	814000	USD
CY2017	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2015	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	12418000	USD
CY2016	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	74075000	USD
CY2017	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	82333000	USD
CY2015	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	3656000	USD
CY2016	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	2409000	USD
CY2017	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	2966000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	468000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	850000	USD
CY2017	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	0	USD
CY2015Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	103400000	USD
CY2017	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	5900000	USD
CY2015	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	141000	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	9716000	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	11522000	USD
CY2015	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	13258000	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	17200000	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	48049000	USD
CY2016	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	7200000	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	805000	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1497000	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6606000	USD
CY2013	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	20100000	USD
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	311000	USD
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	741000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9094000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11474000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4258000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4890000	USD
CY2015	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2016	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	6000	USD
CY2017	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2017	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2016Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	34000	USD
CY2017Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1946000	USD
CY2015	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	147000	USD
CY2016	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	13000	USD
CY2017	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	0	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27142000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29564000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22301000	USD
CY2015	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	647000	USD
CY2016	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1200000	USD
CY2017	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-177289000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-241972000	USD
CY2015	us-gaap	Sales Revenue Net SalesRevenueNet	147000	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	163000	USD
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	20000	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	24000	USD
CY2016Q4	us-gaap	Sales Revenue Net SalesRevenueNet	39000	USD
CY2016	us-gaap	Sales Revenue Net SalesRevenueNet	246000	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	530000	USD
CY2017Q2	us-gaap	Sales Revenue Net SalesRevenueNet	699000	USD
CY2017Q3	us-gaap	Sales Revenue Net SalesRevenueNet	828000	USD
CY2017Q4	us-gaap	Sales Revenue Net SalesRevenueNet	2120000	USD
CY2017	us-gaap	Sales Revenue Net SalesRevenueNet	4177000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	8388000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	8775000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	13933000	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.91
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.86
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.77
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.017
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.016
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.021
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5163899	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.38
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	27690	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	727	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	147663	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	79962	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1024050	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1208542	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	118704000	USD
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	8.93
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	4.87
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	24.45
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	18.43
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	17.82
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	14.05
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	23.84
CY2017Q4	us-gaap	Share Price SharePrice	26.20
CY2015Q4	us-gaap	Share Price SharePrice	17
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6167170	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6857124	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7328131	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.91
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.72
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.16
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.47
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M4D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y5M5D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M23D
CY2012Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5900000	USD
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	7300000	USD
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	6600000	USD
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	12000000	USD
CY2015Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	0	USD
CY2015Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	0	USD
CY2016Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	1000	USD
CY2017Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	192000	USD
CY2016	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	17000	USD
CY2017	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	140000	USD
CY2016	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	18000	USD
CY2017	us-gaap	Standard Product Warranty Accrual Warranties Issued StandardProductWarrantyAccrualWarrantiesIssued	331000	USD
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	158743	shares
CY2017	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	656846	shares
CY2016	us-gaap	Stock Issued During Period Value Employee Stock Ownership Plan StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan	226000	USD
CY2017	us-gaap	Stock Issued During Period Value Employee Stock Ownership Plan StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan	597000	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	103351000	USD
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	83224000	USD
CY2015	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2000000	USD
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2200000	USD
CY2017	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	12100000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	805000	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1497000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6606000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	65991000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	133018000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	77816000	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	161000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	65000	USD
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44998000	shares
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	343000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1101000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2141000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2100000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2016	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	182000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	721000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	943000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	37000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	97000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2016	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2017	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51276000	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54073000	shares
CY2017	axdx	License Agreement LicenseAgreement	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 9. LICENSE AGREEMENTS AND GRANTS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">National Institute of Health Grant</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In February 2015, the National Institute of Health awarded Denver Health and the Company a </font><font style="font-family:Arial;font-size:10pt;">five</font><font style="font-family:Arial;font-size:10pt;">-year, </font><font style="font-family:Arial;font-size:10pt;">$5.0 million</font><font style="font-family:Arial;font-size:10pt;"> grant to develop a fast and reliable identification and categorical susceptibility test for carbepenem-resistant Enterobacteriaceae directly from whole blood. The cumulative award amount under these subawards is </font><font style="font-family:Arial;font-size:10pt;">$885,000</font><font style="font-family:Arial;font-size:10pt;">. The amounts invoiced for the years ended </font><font style="font-family:Arial;font-size:10pt;">December 31, 2017</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;"> was </font><font style="font-family:Arial;font-size:10pt;">$240,000</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$74,000</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$483,000</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Arizona Commerce Authority</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In August 2012, the Company entered into a Grant Agreement (the “Grant Agreement”) with the Arizona Commerce Authority, an agency of the State of Arizona (the “Authority”), pursuant to which the Authority provided certain state and county sponsored incentives for the Company to relocate its corporate headquarters to, and expand its business within, the State of Arizona (the “Project”). Pursuant to the Grant Agreement, the Authority agreed to provide a total grant in the amount of </font><font style="font-family:Arial;font-size:10pt;">$1.0 million</font><font style="font-family:Arial;font-size:10pt;"> (the “Grant”) for the use by the Company in the advancement of the Project. The Grant is payable out of an escrow account in </font><font style="font-family:Arial;font-size:10pt;">four</font><font style="font-family:Arial;font-size:10pt;"> installments, upon the achievement of the following milestones:</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 1 – Relocation of Company’s operations and corporate headquarters to Arizona and creation of </font><font style="font-family:Arial;font-size:10pt;">15</font><font style="font-family:Arial;font-size:10pt;"> Qualified Jobs (as defined below).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 2 – Creation of </font><font style="font-family:Arial;font-size:10pt;">30</font><font style="font-family:Arial;font-size:10pt;"> Qualified Jobs (including Qualified Jobs under Milestone 1).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 3 – Creation of </font><font style="font-family:Arial;font-size:10pt;">40</font><font style="font-family:Arial;font-size:10pt;"> Qualified Jobs (including Qualified Jobs under Milestones 1 and 2).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Milestone 4 – Creation of </font><font style="font-family:Arial;font-size:10pt;">65</font><font style="font-family:Arial;font-size:10pt;"> Qualified Jobs (including Qualified Jobs under Milestones 1, 2 and 3) and capital investment of at least </font><font style="font-family:Arial;font-size:10pt;">$4.5 million</font><font style="font-family:Arial;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For purposes of the Grant Agreement, a “Qualified Job” is a job that is permanent, full-time, new to Arizona, and for which the Company pays average (across all Qualified Jobs identified by the Company in its discretion) annual wages of at least </font><font style="font-family:Arial;font-size:10pt;">$63,000</font><font style="font-family:Arial;font-size:10pt;"> and offers health insurance benefits and pays at least </font><font style="font-family:Arial;font-size:10pt;">65%</font><font style="font-family:Arial;font-size:10pt;"> of the premiums associated with such benefits. The amount of each installment payment will be determined in accordance with a formula specified in the Grant Agreement. The Grant Agreement also contains other customary provisions, including representations, warranties and covenants of both parties. As of </font><font style="font-family:Arial;font-size:10pt;">December 31, 2017</font><font style="font-family:Arial;font-size:10pt;">, the Company has collected all of the </font><font style="font-family:Arial;font-size:10pt;">$1.0 million</font><font style="font-family:Arial;font-size:10pt;"> in milestones. The full amount is recorded in deferred revenue and income until the economic development provisions of the grant have been satisfied in full, as there are “claw-back” provisions which would require repayment of certain amounts received if employment levels are not sustained during the term of the arrangement. Once the “claw-back” provisions expire in January 2018, we will recognize the grant as an offset to expense. Further details are included in </font><font style="font-family:Arial;font-size:10pt;">Note 10, Deferred Revenue and Income</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In January 2018, the “claw-back” provisions expired and the </font><font style="font-family:Arial;font-size:10pt;">$1.0 million</font><font style="font-family:Arial;font-size:10pt;"> was recognized as an offset to expense.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Arizona R&D Refundable Tax Credit Program</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company has applied for and met the program requirements to receive a “Certificate of Qualification” from the Arizona Commerce Authority (“Authority”) which allows the Company to be eligible for a partial refund of research and development investments (“Arizona R&D Refundable Tax Credit Program”). The amounts collected under this program are recorded as an offset to research and development expenses, and for the years ended </font><font style="font-family:Arial;font-size:10pt;">December 31, 2017</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">2016</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">2015</font><font style="font-family:Arial;font-size:10pt;">, were </font><font style="font-family:Arial;font-size:10pt;">$0</font><font style="font-family:Arial;font-size:10pt;">, </font><font style="font-family:Arial;font-size:10pt;">$1.2 million</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">$647,000</font><font style="font-family:Arial;font-size:10pt;">, respectively. If the amount received for this program is later determined to be incorrect or invalid, the excess may need to be repaid.</font></div></div>
CY2017	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable, including receivables from major customers.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company’s main financial institution for banking operations held </font><font style="font-family:Arial;font-size:10pt;">82%</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">57%</font><font style="font-family:Arial;font-size:10pt;"> of the Company’s cash and cash equivalents as of </font><font style="font-family:Arial;font-size:10pt;">December 31, 2017</font><font style="font-family:Arial;font-size:10pt;"> and </font><font style="font-family:Arial;font-size:10pt;">December 31, 2016</font><font style="font-family:Arial;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Company grants credit to domestic and international clients in various industries. Exposure to losses on accounts receivable is principally dependent on each client's financial position. </font></div></div>
CY2017	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Reclassification</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Certain prior year amounts have been reclassified for consistency with the current year presentation and had no effect on our net income, stockholders’ equity or cash flows. In the current period presentation and the revised prior period presentation, depreciation and amortization expenses are reported as a component of the individual costs and expenses as part of the statements of operations and comprehensive loss. </font></div></div>
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;text-align:justify;text-indent:0px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"></font></div></div>

Files In Submission

Name	View Source	Status
0001628280-18-002558-index-headers.html	Edgar Link	pending
0001628280-18-002558-index.html	Edgar Link	pending
0001628280-18-002558.txt	Edgar Link	pending
0001628280-18-002558-xbrl.zip	Edgar Link	pending
axdx-123117x10k.htm	Edgar Link	pending
axdx-12312017xexh21.htm	Edgar Link	pending
axdx-12312017xexh231.htm	Edgar Link	pending
axdx-12312017xexh311.htm	Edgar Link	pending
axdx-12312017xexh312.htm	Edgar Link	pending
axdx-12312017xexh32.htm	Edgar Link	pending
axdx-20171231.xml	Edgar Link	completed
axdx-20171231.xsd	Edgar Link	pending
axdx-20171231_cal.xml	Edgar Link	unprocessable
axdx-20171231_def.xml	Edgar Link	unprocessable
axdx-20171231_lab.xml	Edgar Link	unprocessable
axdx-20171231_pre.xml	Edgar Link	unprocessable
chart-86d8d173b32856908cf.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AXDX
Accelerate Diagnostics, Inc Stock $axdx

2017 Q4 Form 10-K Financial Statement

#000162828018002558 Filed on March 01, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AXDX Accelerate Diagnostics, Inc Stock $axdx

2017 Q4 Form 10-K Financial Statement

#000162828018002558 Filed on March 01, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AXDX
Accelerate Diagnostics, Inc Stock $axdx